Patients' and oncologists' views on the treatment and care of advanced ovarian cancer in the UK: results from the ADVOCATE study

Article English OPEN
Jenkins, V ; Catt, S ; Banerjee, S ; Gourley, C ; Montes, A ; Solis-Trapala, I ; Monson, K ; Fallowfield, L (2013)
  • Publisher: Nature Publishing Group
  • Journal: British Journal of Cancer (issn: 0007-0920, vol: 108, pp: 2,264-2,271)
  • Related identifiers: doi: 10.1038/bjc.2013.223, pmc: PMC3681025
  • Subject: oncologists' views | maintenance therapy | Patient Acceptance of Health Care | Cancer Research | Oncology | advanced ovarian cancer | Medical Oncology | Ovarian Neoplasms | Physician's Practice Patterns | Survival Rate | female | Clinical Study | Great Britain | Middle Aged | Questionnaires | patients' views | Disease-Free Survival | chemotherapy treatments | supportive care | /dk/atira/pure/subjectarea/asjc/2700/2730 | /dk/atira/pure/subjectarea/asjc/1300/1306 | Quality of Life | Humans | Male | R1

Background:Most patients presenting with advanced ovarian cancer (AOC) eventually relapse. Symptom palliation, maintenance of quality of life (QoL) and prolongation of life are primary therapeutic goals.Methods:Sixty-six UK oncologists completed an online survey about AOC management. Two hundred and two patients were interviewed about care, treatment experiences and expectations.Results:Prior to diagnosis, 34% (69 out of 202) of women had 3 symptoms associated with AOC. Twenty-one per cent (43 out of 202) thought poor symptom recognition by general practitioners (GPs) delayed diagnosis. Amelioration of side effects experienced was variable, for example, only 54% (68 out of 127) distressed by alopecia had received sufficient information about it. Clinicians were asked 'What minimum gain in progression-free survival (PFS) would make you feel it worthwhile to offer maintenance therapy?'; 48% (24 out of 50) indicated 5-6 months, but 52% (26 out of 50) believed patients would find PFS of 3-4 months acceptable. When patients were presented with hypothetical scenarios, 33% (52 out of 160) would require 1-2 months extra life, 6% (10 out of 160) 3-4 months, 31% (49 out of 160) 5-6 months, and 31% (49 out of 160) 7 months. However, 86% (173 out of 202) would accept treatment that improved QoL without prolongation of life. When asked what was most important, 33% (67 out of 201) said QoL, 9% (19 out of 201) length of life and 57% (115 out of 201) said both were equally important.Conclusion:Clinicians' and patients' experiences, expectations and priorities about OC management may differ.British Journal of Cancer advance online publication 7 May 2013; doi:10.1038/bjc.2013.223 www.bjcancer.com.
  • References (22)
    22 references, page 1 of 3

    Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5): 365-376.

    Arraras JI, Greimel E, Sezer O, Chie W-C, Bergenmar M, Costantini A, Young T, Velikova G (2010) An international validation study of the EORTC QLQ-INFO25 questionnaires: an instrument to assess the information given to cancer patients. Eur J Cancer 46: 2726-2738.

    Basch E, Abernethy AP (2011) Supporting clinical practice decisions with real-time patient-reported outcomes. J Clin Oncol 29: 954-956.

    Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Liang SX (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer (GOG-0218 study. N Engl J Med 365: 2473-2483.

    Cancer Research UK (2012) Ovarian cancer statistics www.cancerresearchuk. org/cancer-info/cancerstats/types/ovary/(accessed 2 Nov 2012).

    Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstoff ML, Johannesen TB, Adolfsson J, Lambe M, Lawrence G, Meechan D, Morris EJ, Middleton R, Steward J, Richards MA. the ICBP Module 1 Working Group (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377: 127-138.

    Cox A, Bull E, Cockle-Hearne J, Knibb W, Potter C, Faithfull S (2008) Nurse led telephone follow up in ovarian cancer: a psychosocial perspective. Eur J Oncol Nurs 12: 412-417.

    Cox K, Wilson E, Health L, Collier J, Jones L, Johnston I (2006) Preferences for follow-up after treatment for lung cancer. Cancer Nurs 29: 176-187.

    Department of Health National Cancer Patient Experience Survey 2011/12 - National Report 17 August 2012 www.dh.gov.uk/publications.

    Donovan KA, Greene PG, Shuster Jr. JL, Partridge EE, Tucker DC (2002) Treatment preferences in recurrent ovarian cancer. Gynecolog Oncol 86: 200-211.

  • Metrics
    No metrics available
Share - Bookmark